S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Forecast, Price & News

$10.59
-3.01 (-22.13%)
(As of 06/5/2023 ET)
Compare
Today's Range
$10.51
$13.56
50-Day Range
$9.98
$17.27
52-Week Range
$9.74
$28.20
Volume
559,819 shs
Average Volume
225,582 shs
Market Capitalization
$456.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.63

IGM Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
179.7% Upside
$29.63 Price Target
Short Interest
Bearish
23.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
1.46mentions of IGM Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$60,394 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.97) to ($5.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

108th out of 986 stocks

Pharmaceutical Preparations Industry

39th out of 478 stocks


IGMS stock logo

About IGM Biosciences (NASDAQ:IGMS) Stock

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGMS Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
IGM Biosciences (NASDAQ:IGMS) Trading 8.6% Higher
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Analyst Expectations for IGM Biosciences's Future
IGM Biosciences (NASDAQ:IGMS) Price Target Cut to $17.00
Recap: IGM Biosciences Q1 Earnings
IGM Biosciences (NASDAQ:IGMS) Trading Up 18.3%
See More Headlines

IGMS Price History

IGMS Company Calendar

Last Earnings
3/30/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
192
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$29.63
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+179.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-221,100,000.00
Net Margins
-14,363.10%
Pretax Margin
-14,357.64%

Debt

Sales & Book Value

Annual Sales
$1.07 million
Book Value
$6.67 per share

Miscellaneous

Free Float
18,973,000
Market Cap
$456.22 million
Optionable
Not Optionable
Beta
-0.23

Social Links


Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 70)
    CEO, Pres & Director
    Comp: $926.9k
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Bus. Officer
    Comp: $528.18k
  • Dr. Chris H. Takimoto FACP (Age 64)
    M.D., Ph.D., Chief Medical Officer
    Comp: $662.28k
  • Mr. Misbah Tahir (Age 48)
    Chief Financial Officer
  • Mr. Steven Weber (Age 47)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Dr. Bruce A. Keyt (Age 70)
    Chief Scientific Officer
  • Mr. Paul C. Graffagnino
    VP of Legal Affairs
  • Ms. Suzette Tauber (Age 59)
    Chief HR Officer
  • Dr. Shinyu Chen M.D. (Age 54)
    Ph.D., Consultant
  • Dr. Angus M. Sinclair Ph.D.
    Sr. VP of Immuno-Oncology













IGMS Stock - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IGMS shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price forecast for 2023?

7 brokerages have issued 12 month price targets for IGM Biosciences' stock. Their IGMS share price forecasts range from $17.00 to $55.00. On average, they anticipate the company's stock price to reach $29.63 in the next year. This suggests a possible upside of 179.7% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2023?

IGM Biosciences' stock was trading at $17.01 at the start of the year. Since then, IGMS stock has decreased by 37.7% and is now trading at $10.59.
View the best growth stocks for 2023 here
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) announced its quarterly earnings results on Thursday, March, 30th. The company reported ($1.19) EPS for the quarter, topping analysts' consensus estimates of ($1.53) by $0.34. The firm had revenue of $0.37 million for the quarter, compared to the consensus estimate of $15.27 million. IGM Biosciences had a negative net margin of 14,363.10% and a negative trailing twelve-month return on equity of 74.30%. During the same period in the previous year, the business earned ($1.50) earnings per share.

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.92%), FMR LLC (1.96%), BlackRock Inc. (1.79%), State Street Corp (0.53%), Geode Capital Management LLC (0.46%) and Candriam S.C.A. (0.44%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Redmile Group, Llc.
View institutional ownership trends
.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $10.59.

How much money does IGM Biosciences make?

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $456.22 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis.

How many employees does IGM Biosciences have?

The company employs 192 workers across the globe.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.

This page (NASDAQ:IGMS) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -